← Leaderboards
James C Willey
Massachusetts Institute Of Technology
$6,359,705
Attributed
$6,702,560
Total exposure
9
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2005–14$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
Funding mix
By agency
NIH$6,702,560 · 9
By mechanism
R01$1,879,623 · 1
RC2$1,649,791 · 1
R21$1,217,793 · 4
R24$935,374 · 1
U01$797,914 · 1
P01$222,065 · 1
Top collaborators
- Tony E Godfrey2 shared
- Tom B Morrison2 shared
- John C Anders1 shared
- Tanya Kanigan1 shared
Most similar at Massachusetts Institute Of Technology
Same institution · by research overlap
- Lev T. Perelman$24,479,528
- Steven A. Carr$47,532,757
- Karl D Wittrup$33,463,127
- Shelly R. Peyton$5,501,603
- Alex K Shalek$15,014,003
Others in their field
Top investigators on “Biomarker”
- David R. Weir · University Of Michigan At Ann Arbor$368,126,077
- Leonard Freedman · Leidos Biomedical Research, Inc.$248,231,562
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$217,859,034
- Ralph Parchment · Leidos Biomedical Research, Inc.$186,322,680
- Randall J Bateman · Washington University$182,177,358
- Paul S. Aisen · Cognition Therapeutics, Inc.$182,141,353
Research focus
BiomarkerGene ExpressionNeoplasm /Cancer GeneticsGenesBaseLeadMalignant Neoplasm Of LungPolymerase Chain ReactionMalignant NeoplasmsInnovationFundingDiagnostic TestsTranscriptCancer RiskSamplingOperative Surgical ProceduresMeasurementMolecular Biology Information SystemFreezingDesignDrug ResistanceNonsmall Cell Lung CancerEpithelial CellsClinical Research
Grant awards (24)
Inherited genetic risk factors common to COPD and lung cancer.$396,157
R01 · FY2014 · HL · contact PI
Inherited genetic risk factors common to COPD and lung cancer.$465,981
R01 · FY2013 · HL · contact PI
Inherited genetic risk factors common to COPD and lung cancer.$465,613
R01 · FY2012 · HL · contact PI
Inherited genetic risk factors common to COPD and lung cancer.$551,872
R01 · FY2011 · HL · contact PI
Implementation of innovative RNA sample quality control methods$190,982
R21 · FY2011 · CA · contact PI
Validation of a multi-gene test for lung cancer risk$850,365
RC2 · FY2010 · CA · contact PI
Implementation of innovative RNA sample quality control methods$194,432
R21 · FY2010 · CA · contact PI
Validation of a multi-gene test for lung cancer risk$799,426
RC2 · FY2009 · CA · contact PI
Standardized NanoArray PCR for Gene Expression Profiling of Lung Cancer$153,845
R21 · FY2009 · CA · contact PI
Standardized NanoArray PCR for Gene Expression Profiling of Lung Cancer$70,600
R21 · FY2009 · CA
Standardized NanoArray PCR for Gene Expression Profiling of Lung Cancer$249,250
R21 · FY2008 · CA
Standardized Gene Expression Core Facility Development$165,472
R24 · FY2006 · CA · contact PI
Standardized Gene Expression Core Facility Development$165,144
R24 · FY2005 · CA
Standardized Gene Expression Core Facility Development$180,334
R24 · FY2004 · CA
Lung Cancer Diagnostic Test Validation in FNA Specimens$142,684
R21 · FY2004 · CA
GENE EXPRESSION INDICES IN CHEMORESISTANT LUNG CANCER$208,408
U01 · FY2003 · CA
Standardized Gene Expression Core Facility Development$199,664
R24 · FY2003 · CA
Standardized Gene Expression Core Facility Development$224,760
R24 · FY2002 · CA
GENE EXPRESSION INDICES IN CHEMORESISTANT LUNG CANCER$202,337
U01 · FY2002 · CA
GENE EXPRESSION INDICES IN CHEMORESISTANT LUNG CANCER$196,445
U01 · FY2001 · CA
GENE EXPRESSION INDICES ASSOCIATED WITH CHEMORESISTANCE$108,000
R21 · FY2001 · CA
CORE--HUMAN CELL AND TISSUE ACQUISITION$222,065
P01 · FY2000 · ES
GENE EXPRESSION INDICES IN CHEMORESISTANT LUNG CANCER$190,724
U01 · FY2000 · CA
GENE EXPRESSION INDICES ASSOCIATED WITH CHEMORESISTANCE$108,000
R21 · FY2000 · CA